Artrya Limited · ASX:AYA
Artrya — Investor Presentation (October 2024)
20 slides from Artrya's investor presentation, Oct 15, 2024
Slide 1: October 2024 Artrya Presentation Deck
For personal use only October 2024 ARTRYA Presentation Deck 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation IMPORTANT NOTICE including, without limitation, any financial information, any estimates or pro
Slide 3: Company Snapshot
Company Snapshot Share Price Performance $0.45 $0.40 $0.35 For personal use only $0.30 $0.25 $0.20 $0.15 $0.10 $0.05 $0.00 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Mar-24 Apr -24 May-24 Jun-24 Jul-24 Aug -24 Sep -24 Oct-24 Key Statistics Shareholding Overview Shares on issue: 78.8m Options: 29.1m Market c
Slide 4: Board of Directors, CEO, and Co-Founder
Board of Directors, CEO, and Co-Founder For personal use only Chair Non-Executive Director Non-Executive Director Chief Executive Officer Co-founder Bernie Ridgeway Kate Hill Jacque Sokolov, MD Mathew Regan John Konstantopoulos Bernie brings a wealth of Ms Hill is an experienced non- Jacque J. Sokol
Slide 5: Executive Summary
Executive Summary • Medical technology company founded in 2019. • Artrya has developed unique, cloud-based AI solutions targeting cardiac CT imaging that assist in real-time heart disease diagnosis. • The point-of-care platform, Salix®, helps to improves patient outcomes, lowers the cost to serve fo
Slide 6: A large, growing, and inadequately served market
For personal use only A large, growing, and inadequately served market 6
Slide 7: Heart disease kills more people than all cancers combined
Heart disease kills more people than all cancers combined Outdated methods lead to suboptimal patient outcomes, unnecessary cost, and reduce system efficiency For personal use only Old methods are ineffective Most procedures are unnecessary In detecting high high-risk plaques that 55% of invasive pr
Slide 8: Salix is unique in providing real-time patient diagnosis and triage
Salix® is unique in providing real-time patient diagnosis and triage Point of care enabling real-time plaque analysis For personal use only Provides real-time analysis of CCTA scans. This includes quantitative plaque assessment, stenosis, calcium score, and FFR assessment* Single Reporting Platform
Slide 9: Seamlessly fits into workflow
Seamlessly fits into workflow Salix® is system agnostic and simple to deploy, use, and update Onsite Manual Assessment Review & Prepare Report For personal use only Manual assessment | No plaque assessment | Limited access to reimbursement Offsite ‘Human in the loop’ Clinician Receives Report Requir
Slide 10: Salix delivers benefits across the entire value chain
Salix® delivers benefits across the entire value chain For personal use only Patients Providers Payers Increased Efficiency and Reduction in overall cost Better patient outcomes Revenue Growth of care • Earlier identification and treatment • Improved quality of care • Reduction in total cost of care
Slide 11: Salix is built to target all pillars across the care continuum
Salix® is built to target all pillars across the care continuum Artrya’s product pipeline goes further & moves us towards predicting the patient at risk. For personal use only Whole Heart Disease Structural Optimised Characterisation Severity Assessment Procedure Detailed Plaque and Dispersion Non-i
Slide 12: Salix Demonstration
Salix® Demonstration For personal use only 12
Slide 13: Backed by robust evidence and patents
Backed by robust evidence and patents Developed and trained on more than 5 million CT images Key Clinical Studies and Publications Coronary Artery Stenosis and High-Risk Plaque Assessed For personal use only with Unsupervised Fully Automated Deep Learning Technique Evaluation of an artificial intell
Slide 14: Market Adoption
For personal use only 14 Market Adoption
Slide 15: Heart disease is a large and growing health challenge
Heart disease is a large and growing health challenge 12.6 million CCTA scans (RoW)2 For personal use only US$4.18 billion* Serviceable Addressable Market (US) 6.2% YOY 4.4 Projected growth in Cardiac U.S. patients undergoing CCTA million CCTA CCTA scans to 20281 scans2 Targeted Approach in US Green
Slide 16: Attractive SaaS pricing model
Attractive SaaS pricing model Hybrid approach subscription and fee-per-analysis pricing model based on volume with a highly attractive revenue-sharing pricing structure For personal use only Revenue Model Benefits Tiered subscription • Positions Artrya as a single CCTA reporting platform Single plat
Slide 17: Competitive Positioning
Competitive Positioning Salix® is fasted and places the specialist at the centre of care which is important for reimbursement Point of care (Highly scalable) For personal use only • No Vulnerable Plaque assessment • Slow and manual assessment • Scale limited by business model • Access to reimburseme
Slide 18: Regulatory approval and pathway to revenue
Regulatory approval and pathway to revenue REGULATORY APPROVALS SH ORTENING THE PATH WAY TO R EVEN UE For personal use only Australia US agreements pre-FDA clearance New Zealand Customers in Australia European CE Mark UK Conformity Assessment Submitted FDA strategy (Indicative timeframe) • Estimated
Slide 19: Strategic Agreements and Partnerships
Strategic Agreements and Partnerships Strategic Agreements Research Partnerships For personal use only Research Partnerships • Three Strategic 5-year agreements to deploy Salix® upon FDA approval. • Artrya is in various stages of discussions with leading US healthcare systems and expect to have robu
Slide 20: Thank You
For personal use only 20 Thank You